MARK E. DELANEY - 18 Nov 2025 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)

Signature
Sean D. Mersten, Attorney in Fact for Mark E. Delaney
Issuer symbol
DGX
Transactions as of
18 Nov 2025
Net transactions value
-$1,488,683
Form type
4
Filing time
20 Nov 2025, 16:28:10 UTC
Previous filing
24 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DELANEY MARK E SVP & Chief Commercial Officer 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS Sean D. Mersten, Attorney in Fact for Mark E. Delaney 20 Nov 2025 0001955265

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DGX Common Stock Options Exercise $1,133,512 +7,846 +104% $144.47 15,376 18 Nov 2025 Direct F1
transaction DGX Common Stock Options Exercise $14,333 +100 +0.65% $143.33 15,476 18 Nov 2025 Direct F1
transaction DGX Common Stock Sale $1,488,683 -7,946 -51% $187.35 7,530 18 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DGX Non-Qualifed Stock Option (right to buy) Options Exercise $1,133,512 -7,846 -100% $144.47 0 18 Nov 2025 Common Stock 7,846 $144.47 Direct F1, F2
transaction DGX Non-Qualifed Stock Option (right to buy) Options Exercise $14,333 -100 -1.3% $143.33 7,484 18 Nov 2025 Common Stock 100 $143.33 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F2 The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.